MediWound Overview
MediWound offers next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWound’s first product, NexoBrid, is a commercial, FDA approved orphan biologic drug for early non-surgical eschar removal of deep-partial and full-thickness thermal burns. It is a bromelain-based gel containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. EscharEx is MediWound’s leading biologic currently in development, utilizing the same active pharmaceutical ingredient found in NexoBrid. It is specifically designed for the debridement of chronic and hard-to-heal wounds. MW005 is an innovative topical biological drug currently in development to address the treatment needs of low-risk Basal Cell Carcinoma (BCC).
Cumulative Funding Raised Over Time ($)
$9.0MFeb 2022
$17.0MFeb 2023
$23.7MJul 2024
$41.7MJun 2013
$71.7MOct 2022
$101.7MSep 2025
Latest News
growth-positive
MediWound announces $30M registered direct offering
MediWound announced a definitive securities purchase agreement for a registered direct offering led by a prominent U.S.-based mutual fund and other healthcare-focused investors. The offering involves the sale of 1,734,105 ordinary shares at $17.30 per share, expected to close around September 30, 2025. The gross proceeds are anticipated to be approximately $30 million, which will be used to support EscharExs pre-commercial activities, enhance manufacturing capabilities, and for general corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent for the offering. This development is seen as a positive growth indicator for MediWound, supporting its financial stability and expansion plans.
PIPE
growth-positive
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Ltd., a biotechnology company specializing in enzymatic therapies for tissue repair, announced a $30 million registered direct offering of ordinary shares. The offering is led by a prominent U.S.-based mutual fund and other healthcare-focused investors. H.C. Wainwright & Co. is acting as the exclusive placement agent. The proceeds will support pre-commercial activities for EscharEx, enhance manufacturing capabilities, and cover general corporate purposes. MediWounds FDA-approved product, NexoBrid, is used for enzymatic removal of eschar in thermal burns and is marketed globally. EscharEx, a late-stage investigational therapy, targets chronic wounds and presents a significant market opportunity.
PIPE/POInvestment
growth-positive
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, has received marketing approval from Australias Therapeutic Goods Administration (TGA) for its product NexoBrid®, an enzymatic therapy for burn treatment. This approval marks a significant milestone for MediWound, as NexoBrid is now authorized in 45 countries, enhancing its global reach. The companys partner in Australia, Balance Medical, plans to launch the product in the fourth quarter of 2025. This development not only strengthens MediWounds presence in Australia but also opens opportunities in the broader Asia-Pacific region. MediWound is preparing for increased demand with a manufacturing expansion set to complete by the end of 2025.
Product StagePartners
growth-negative
MediWound's (NASDAQ:MDWD) investors will be pleased with their notable 84% return over the last three years
MediWound Ltd. has experienced a significant stock price increase of 84% over the past three years, outperforming the market. However, the companys revenue has been shrinking by 7.4% annually over the same period, raising concerns about its long-term profitability. Despite the lack of revenue growth, the stock has returned 23% compounded over three years. The article suggests that while the company has shown some positive stock performance, its financial health remains a concern due to the absence of profitability and declining revenue. MediWound is involved in the healthcare sector, with AI being a potential transformative factor in the industry.
growth-positive
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced its participation at the 21st European Burns Association Congress in Berlin, Germany. The companys product, NexoBrid®, an enzymatic burn debridement therapy, will be featured in 36 scientific presentations. These presentations will highlight NexoBrids benefits in burn care, including improved survival, recovery, and scar outcomes. The product is approved in over 40 countries, including the U.S., EU, and Japan. The development of NexoBrid has been supported by BARDA, which funded pivotal clinical studies and the marketing approval process. The congress will further establish NexoBrids role in advancing burn care.
Product StageCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $198.72M |
| Last funding | $30M |
| Stage | Public |
| Rounds | 8 |
| Investors | 10 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | mediwound.com |
| Careers | Careers page |
Locations
42 Hayarkon Street, Yavne, Israel
Wilmington, DE, USA
65428 Rüsselsheim, Germany
Photos & Videos
1 item(s)
MediWound Business
Business models
B2B2C
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (8)
tissue-regenerationdermatologyburnsbiotechnologytopical-treatmentpatientspharma-companiespharmaceuticalsGeographic Markets
United Arab EmiratesEuropeNorth AmericaMediWound Financials
$198.72M
Total funding
Undisclosed
Capital raised
$30M
Last funding
Public
Funding stage
8
Total rounds
10
Investors
Cumulative Funding Raised Over Time ($)
$9.0MFeb 2022
$17.0MFeb 2023
$23.7MJul 2024
$41.7MJun 2013
$71.7MOct 2022
$101.7MSep 2025
Private Equity Funding
PIPE
Sep 2025
$30M
PIPE
Jul 2024
$6.69M
Mölnlycke Health Care (Lead)
,
Yalin Lapidot
PIPE
Feb 2023
$8.03M
Israel Biotech Fund, Sol J. Barer, aMoon Fund, Deep Insight, Point72 Ventures
PIPE
Oct 2022
$30M
New Era Capital Partners, Deep Insight
PIPE
Feb 2022
$9M
Biomedical Advanced Research and Development Authority (BARDA)
Undisclosed Round
Jun 2013
$18M
Clal Biotechnology Industries (CBI)
Public Offering / Exit
POEvent
Jun 2017
Undisclosed
POEvent
Mar 2014
Undisclosed
Mergers & Acquisitions
MNAEvent
Nov 2017
$1.5M
MediWound Lifecycle
Cumulative Funding Raised Over Time
$9.0MFeb 2022
$17.0MFeb 2023
$23.7MJul 2024
$41.7MJun 2013
$71.7MOct 2022
$101.7MSep 2025
All Events
PIPE
Sep 2025
$30M
PIPE
Jul 2024
$6.69M
Mölnlycke Health Care (Lead)
,
Yalin Lapidot
PIPE
Feb 2023
$8.03M
Israel Biotech Fund, Sol J. Barer, aMoon Fund, Deep Insight, Point72 Ventures
PIPE
Oct 2022
$30M
New Era Capital Partners, Deep Insight
PIPE
Feb 2022
$9M
Biomedical Advanced Research and Development Authority (BARDA)
Undisclosed Round
Jun 2013
$18M
Clal Biotechnology Industries (CBI)
POEvent
Jun 2017
Undisclosed
POEvent
Mar 2014
Undisclosed
MNAEvent
Nov 2017
$1.5M
MediWound News
189 articles
growth-positive
MediWound announces $30M registered direct offering
MediWound announced a definitive securities purchase agreement for a registered direct offering led by a prominent U.S.-based mutual fund and other healthcare-focused investors. The offering involves the sale of 1,734,105 ordinary shares at $17.30 per share, expected to close around September 30, 2025. The gross proceeds are anticipated to be approximately $30 million, which will be used to support EscharExs pre-commercial activities, enhance manufacturing capabilities, and for general corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent for the offering. This development is seen as a positive growth indicator for MediWound, supporting its financial stability and expansion plans.
PIPE
growth-positive
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Ltd., a biotechnology company specializing in enzymatic therapies for tissue repair, announced a $30 million registered direct offering of ordinary shares. The offering is led by a prominent U.S.-based mutual fund and other healthcare-focused investors. H.C. Wainwright & Co. is acting as the exclusive placement agent. The proceeds will support pre-commercial activities for EscharEx, enhance manufacturing capabilities, and cover general corporate purposes. MediWounds FDA-approved product, NexoBrid, is used for enzymatic removal of eschar in thermal burns and is marketed globally. EscharEx, a late-stage investigational therapy, targets chronic wounds and presents a significant market opportunity.
PIPE/POInvestment
growth-positive
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, has received marketing approval from Australias Therapeutic Goods Administration (TGA) for its product NexoBrid®, an enzymatic therapy for burn treatment. This approval marks a significant milestone for MediWound, as NexoBrid is now authorized in 45 countries, enhancing its global reach. The companys partner in Australia, Balance Medical, plans to launch the product in the fourth quarter of 2025. This development not only strengthens MediWounds presence in Australia but also opens opportunities in the broader Asia-Pacific region. MediWound is preparing for increased demand with a manufacturing expansion set to complete by the end of 2025.
Product StagePartners
growth-negative
MediWound's (NASDAQ:MDWD) investors will be pleased with their notable 84% return over the last three years
MediWound Ltd. has experienced a significant stock price increase of 84% over the past three years, outperforming the market. However, the companys revenue has been shrinking by 7.4% annually over the same period, raising concerns about its long-term profitability. Despite the lack of revenue growth, the stock has returned 23% compounded over three years. The article suggests that while the company has shown some positive stock performance, its financial health remains a concern due to the absence of profitability and declining revenue. MediWound is involved in the healthcare sector, with AI being a potential transformative factor in the industry.
growth-positive
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced its participation at the 21st European Burns Association Congress in Berlin, Germany. The companys product, NexoBrid®, an enzymatic burn debridement therapy, will be featured in 36 scientific presentations. These presentations will highlight NexoBrids benefits in burn care, including improved survival, recovery, and scar outcomes. The product is approved in over 40 countries, including the U.S., EU, and Japan. The development of NexoBrid has been supported by BARDA, which funded pivotal clinical studies and the marketing approval process. The congress will further establish NexoBrids role in advancing burn care.
Product StageCustomers
growth-positive
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediWound Ltd., a biotechnology company specializing in enzymatic therapies for tissue repair, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The companys FDA-approved product, NexoBrid®, is used for enzymatic removal of eschar in thermal burns and is available in multiple international markets. MediWound is also developing EscharEx®, a late-stage investigational therapy for chronic wound debridement, which has shown clinical advantages over existing products. The event will be webcast live, providing an opportunity for investors to learn more about MediWounds advancements and market potential.
Product StageCustomers
growth-negative
Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) Second-Quarter Report
MediWound Ltd. recently reported its quarterly results, which led to a 2.8% drop in its share price to US$18.10. While revenues met expectations at US$5.7 million, statutory losses increased significantly to US$1.23 per share. Analysts have mixed opinions on the companys future, with a consensus revenue forecast of US$24.1 million for 2025, reflecting a 21% increase. However, losses are expected to rise to US$2.75 per share. Despite the higher forecast losses, the consensus price target remains at US$30.67. MediWounds growth rate is expected to accelerate, with revenues projected to grow 47% annually until 2025, outperforming the broader industrys 8.3% growth estimate.
growth-negative
MediWound Second Quarter 2025 Earnings: EPS Misses Expectations
MediWound reported a revenue of US$5.71 million for the latest quarter, marking a 13% increase from the previous quarter. However, the company experienced a net loss of US$13.3 million, which widened by 111% compared to the previous quarter. The earnings per share (EPS) also deteriorated to a loss of US$1.23 per share. Despite the negative earnings report, revenue is forecasted to grow at an average of 36% per annum over the next three years, significantly outpacing the US pharmaceuticals industrys growth forecast of 8.1%. The companys share price remained stable over the past week.
growth-negative
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
MediWound reported a quarterly loss of $1.23 per share, missing the Zacks Consensus Estimate of a $0.55 loss. This represents an earnings surprise of -123.64%. Despite surpassing revenue estimates with $5.71 million, the companys shares have underperformed the market, gaining only 5.3% compared to the S&P 500s 10% gain. The companys earnings outlook remains uncertain, with mixed estimate revisions leading to a Zacks Rank #3 (Hold). The current consensus EPS estimate for the coming quarter is -$0.64 on $6.68 million in revenues.
growth-negative
MediWound: Q2 Earnings Snapshot
MediWound Ltd., based in Yavne, Israel, reported a loss of $13.3 million in its second quarter, equating to a loss of $1.23 per share. This result did not meet Wall Street expectations, which anticipated a loss of 55 cents per share according to analysts surveyed by Zacks Investment Research. Despite the loss, the companys revenue for the period was $5.7 million, slightly exceeding the forecasted $5.6 million. MediWound specializes in developing treatments for burns and hard-to-heal wounds.
growth-positive
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced positive developments in its operations and clinical trials. The company is actively enrolling patients in the VALUE Phase III trial for EscharEx® to treat venous leg ulcers, with new partnerships established with Essity and Convatec. NexoBrid® is gaining commercial traction in the U.S., supported by Vericel, MediWounds exclusive U.S. partner. The company is expanding its manufacturing capacity, with full operational readiness expected by the end of 2025. Additionally, MediWound received $3.6 million in funding from the U.S. Department of Defense to develop a room temperature-stable formulation of NexoBrid. These developments indicate strong growth potential for MediWound.
Product StagePartnersCustomersExpand
growth-positive
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced new data from a Phase II clinical trial of EscharEx, demonstrating a strong correlation between wound bed preparation and wound closure in venous leg ulcers. The study, published in Advances in Wound Care, involved 119 patients and highlighted the importance of complete debridement and timely granulation tissue coverage. Key findings showed that wounds achieving wound bed preparation were significantly more likely to heal, reinforcing EscharExs potential to improve healing outcomes. This data underscores the critical role of wound bed preparation in managing chronic wounds, offering promising implications for MediWounds therapeutic approach.
Product Stage
growth-positive
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Nektar Therapeutics reported a quarterly loss of $2.95 per share, which was better than the Zacks Consensus Estimate of a $3.13 loss. This represents an earnings surprise of +5.75%. The company posted revenues of $11.18 million, surpassing the consensus estimate by 3.66%. Despite a year-over-year revenue decline, Nektar shares have risen by about 61% since the start of the year, outperforming the S&P 500s gain of 7.9%. The earnings outlook and estimate revisions will be crucial for future stock movements. Currently, Nektar holds a Zacks Rank #3 (Hold), indicating expected market performance alignment.
growth-positive
MediWound to Report Second Quarter 2025 Financial Results
MediWound Ltd., a biotechnology company specializing in enzymatic therapies for tissue repair, announced it will release its second quarter 2025 financial results on August 14, 2025. The company will host a conference call and webcast to discuss these results and provide corporate updates. MediWounds FDA-approved product, NexoBrid®, is used for enzymatic removal of eschar in thermal burns and is marketed globally. The company is also advancing EscharEx®, a late-stage investigational therapy for chronic wounds. This announcement highlights MediWounds continued growth and market presence in enzymatic therapeutics.
Product StageCustomers
growth-positive
Here's What Could Help MediWound (MDWD) Maintain Its Recent Price Strength
The article discusses MediWound (MDWD) as a strong candidate for trend investing due to its recent price strength and solid fundamentals. Over the past 12 weeks, the stock has gained 18.6%, and it continues to show a positive trend with a 7.6% increase over the last four weeks. MediWound is trading at 82% of its 52-week high-low range, suggesting potential for a breakout. The stock carries a Zacks Rank #1 (Strong Buy), placing it in the top 5% of stocks based on earnings estimate revisions and EPS surprises. This ranking system has historically generated significant returns, making MediWound a compelling choice for investors.
growth-positive
MediWound Ltd. (NASDAQ:MDWD) is definitely on the radar of institutional investors who own 42% of the company
The article discusses the substantial influence institutional investors have on MediWound Ltd., as they hold a significant portion of the companys shares, with institutions owning around 42% of the stock. Clal Life Sciences L.P. is the largest shareholder, followed by Mölnlycke Health Care AB and Investor AB (publ). The presence of institutional investors is generally viewed positively, as it suggests credibility and potential for growth. However, the article also cautions that large institutional sell-offs could negatively impact the share price. The CEO, Ofer Gonen, holds 1.7% of the shares, and the top 8 shareholders collectively own more than half of the companys shares.
growth-negative
Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth
MediWound, a company listed on NASDAQ under the ticker MDWD, is currently facing challenges related to its cash burn rate. As of March 2025, the company had cash reserves of $38 million and a cash burn rate of $19 million per year, giving it a cash runway of approximately two years. Despite reducing its cash burn by 13% over the past year, the company experienced a revenue dip of 3.2%. This situation raises concerns about its growth trajectory and the potential need to raise additional capital through debt or equity. The article emphasizes the importance of monitoring the companys financial health and future growth prospects.
Oppenheimer assumes MediWound stock at outperform, sets $34 PT
growth-negative
MediWound Ltd (MDWD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline
MediWound Ltd reported a decrease in total revenue to $4 million in Q1 2025 from $5 million in Q1 2024, primarily due to lower BARDA-funded development services revenue. Despite this, the company is making progress with its VALUE Phase 3 trial of EscharEx and has secured a EUR2.5 million grant from the European Innovation Council Accelerator. The company is expanding its manufacturing capabilities with a new facility expected to be operational by the end of 2025. However, there is uncertainty regarding FDA inspections for the new facility, which could impact future production timelines. Additionally, a potential EUR13.75 million equity investment may not materialize, affecting future project funding.
Product StageInvestmentPartnersExpand
growth-positive
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
MediWound Ltd. announced its first-quarter 2025 financial results and provided updates on its clinical and operational progress. The company is advancing its VALUE Phase III trial for EscharEx in venous leg ulcers, with recruitment underway and an interim assessment expected in mid-2026. MediWound has secured a €2.5 million grant from the European Innovation Council to support EscharExs development for diabetic foot ulcers. Strategic partnerships with companies like Kerecis, Solventum, Mölnlycke, and MIMEDX are bolstering its clinical research programs. The company is also expanding its NexoBrid manufacturing capabilities, aiming for full operational capacity by the end of 2025. These developments reflect strong industry validation and support MediWounds growth trajectory.
Product StagePartnersInvestment
growth-negative
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a $0.65 loss. However, the companys revenue of $3.96 million missed the consensus estimate by 22.39% and was lower than the previous years $4.96 million. Despite outperforming the market with a 17.3% share price increase since the beginning of the year, the companys future performance remains uncertain. The Zacks Rank for MediWound is currently #3 (Hold), indicating expected market-aligned performance. The companys earnings outlook and estimate revisions will be crucial for future stock movements.
growth-negative
MediWound: Q1 Earnings Snapshot
MediWound Ltd., based in Yavne, Israel, reported a first-quarter loss of $726,000, or 7 cents per share, which was better than the expected loss of 65 cents per share according to analysts surveyed by Zacks Investment Research. Despite exceeding expectations in terms of loss per share, the companys revenue of $4 million fell short of the anticipated $5.1 million. MediWound specializes in developing treatments for burns and hard-to-heal wounds. The financial results indicate a growth-negative impact due to the revenue shortfall, despite the better-than-expected loss per share.
growth-positive
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
MediWound Ltd. announced the publication of a post hoc analysis in the journal Wounds, highlighting the superior clinical performance of its product EscharEx® compared to SANTYL® in treating venous leg ulcers. The analysis, based on the Phase II ChronEx clinical trial, demonstrated that EscharEx achieved faster and more effective debridement and wound bed preparation than SANTYL. Key findings included a higher percentage of complete debridement and wound bed preparation in EscharEx-treated patients. Safety profiles were comparable between the two treatments, with EscharEx showing a lower incidence of deep wound infections. These results support EscharExs potential as a leading enzymatic debridement agent.
Product Stage
growth-positive
MediWound to Report First Quarter 2025 Financial Results
MediWound Ltd., a global biotechnology company specializing in enzymatic therapies for tissue repair, announced it will release its financial results for the first quarter of 2025 on May 21. The company will host a conference call and webcast to discuss these results and provide corporate updates. MediWounds FDA-approved product, NexoBrid®, is used for enzymatic removal of eschar in thermal burns and is marketed globally. The company is also developing EscharEx®, a late-stage investigational therapy for chronic wound debridement, which has shown clinical advantages over existing products. This announcement highlights MediWounds ongoing efforts to expand its market presence and product offerings.
Product StagePublic Trading
growth-positive
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, is presenting new data on its investigational therapy, EscharEx, at two major wound care conferences. The data highlights EscharExs mechanism of action and its advantages over existing treatments like SANTYL®. The company is currently conducting a Phase III study for venous leg ulcers (VLUs) and planning a trial for diabetic foot ulcers (DFUs). These findings support the ongoing clinical development of EscharEx, which has shown promise in enhancing wound care practices. MediWound aims to offer a non-surgical solution for chronic wound management, targeting a significant global market.
Product StagePublic Trading
growth-negative
Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%
MediWound Ltd. has experienced a challenging quarter, with its share price dropping by 15%. Over the past five years, the stock has risen by 30%, but this is below the market return of 109%. The company has not been profitable in the last year, and its revenue has been declining at a rate of 5.7% per year over the last five years. Despite these challenges, the stock has managed to increase by 5% annually during this period. Investors faced an 11% loss over the past year, compared to a market gain of 7.4%. The article suggests that the recent sell-off might present an opportunity if the company can return to growth.
growth-positive
MediWound Ltd (MDWD) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Losses
MediWound Ltd reported significant progress in 2024, with a focus on clinical development, commercial expansion, and strategic partnerships. The company achieved a revenue of $20.2 million, with a projected growth to $24 million in 2025. Despite an operating loss of $19.4 million and a net loss of $30.2 million, the company secured EUR16.5 million in funding from the European Innovation Council to accelerate the development of EscharEx for diabetic foot ulcers. Additionally, MediWound strengthened its financial position with a $25 million PIPE financing round. The companys gross profit margin declined due to changes in revenue mix and higher fixed costs. EscharEx showed superiority in clinical trials, and NexoBrid achieved significant commercial reach.
InvestmentPIPEPartnersProduct Stage
growth-positive
Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term
MediWound Ltd., a biopharmaceutical company, is on the verge of a significant milestone as it approaches breakeven. The company, which specializes in non-surgical solutions for tissue repair, posted a loss of $30 million in the last financial year but is expected to become profitable by 2027. Analysts predict an optimistic annual growth rate of 58% to achieve this target. Notably, MediWound operates without debt, relying solely on shareholder funding, which reduces investment risk. While the article provides a high-level overview, it highlights the companys potential for growth and profitability, emphasizing its unique position in the market.
growth-negative
MediWound: Q4 Earnings Snapshot
MediWound Ltd., based in Yavne, Israel, reported a financial loss of $3.9 million in the fourth quarter, translating to a loss of 36 cents per share. This result was better than the anticipated loss of 59 cents per share, as estimated by analysts surveyed by Zacks Investment Research. The company, which specializes in developing treatments for burns and hard-to-heal wounds, posted a revenue of $5.8 million for the quarter, aligning with market forecasts. Over the entire year, MediWound reported a total loss of $30.2 million, or $3.03 per share, with an annual revenue of $20.2 million.
growth-positive
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
MediWound Ltd. has initiated a global Phase III pivotal trial for EscharEx®, targeting venous leg ulcers, and expanded its strategic research collaborations with industry leaders, including Kerecis. The company reported $20 million in revenue for 2024 and projects $24 million for 2025, with $44 million in cash by the end of 2024. MediWound has also secured €16.5 million in funding from the European Innovation Council to accelerate EscharExs development for diabetic foot ulcers. The company plans a Phase II study in 2025 to support a U.S. Biologics License Application. Partnerships with Solventum, Mölnlycke, MIMEDX, and Kerecis are enhancing study execution. EscharEx has shown superiority over SANTYL® in clinical outcomes, with a projected U.S. market share of 22% and peak sales of $725 million.
Product StagePartnersInvestment
growth-positive
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound reported a quarterly loss of $0.36 per share, which was better than the Zacks Consensus Estimate of a $0.59 loss. This represents an earnings surprise of 38.98%. The company, which develops treatments for burns and hard-to-heal wounds, posted revenues of $5.84 million, surpassing the consensus estimate by 1.53%. Despite a loss of $0.98 per share in the previous quarter, MediWound has outperformed the market with an 8.3% increase in shares since the start of the year. The companys future stock performance will depend on managements commentary and earnings outlook. Currently, MediWound holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance.
growth-positive
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced it will release its financial results for Q4 and full year ending December 31, 2024, on March 19, 2025. The company will host a conference call and webcast to discuss these results and provide corporate updates. MediWounds NexoBrid® is an FDA- and EMA-approved drug for burn treatment, while EscharEx®, currently in Phase III development, shows promise for chronic wound debridement. The companys innovative biologics aim to improve patient care and reduce healthcare costs, presenting significant market growth opportunities.
Product Stage
growth-positive
Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates
Madrigal reported a quarterly loss of $2.71 per share, which was better than the Zacks Consensus Estimate of a $4.12 loss, marking an earnings surprise of 34.22%. The company also posted revenues of $103.32 million, surpassing the consensus estimate by 1.69%. This is a significant improvement compared to zero revenues a year ago. Despite underperforming the S&P 500 since the beginning of the year, Madrigals earnings outlook remains a key focus for investors. The companys shares have added about 0.3% since the start of the year. The Zacks Rank for Madrigal is currently #3 (Hold), indicating that the stock is expected to perform in line with the market in the near future.
growth-positive
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
MediWound Ltd. announced the results of its Phase III Children Innovative Debridement Study (CIDS) published in the Burns Journal, highlighting the efficacy and safety of NexoBrid® for pediatric patients with deep thermal burns. The study, conducted across 36 burn centers globally, demonstrated that NexoBrid achieved faster eschar removal, reduced the need for surgical excision, and maintained comparable long-term outcomes to the standard of care (SOC). NexoBrid is approved for pediatric use in the U.S., E.U., and Japan, reinforcing its role as a transformative, non-surgical treatment for burn care. The findings support NexoBrids clinical benefits and its significance in improving outcomes for pediatric burn patients.
Product Stage
growth-positive
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced its participation in the 45th Annual TD Cowen Health Care Conference. CEO Ofer Gonen will present a corporate overview, and the management team will host one-on-one meetings with investors. MediWound specializes in non-surgical tissue repair, with its FDA-approved drug NexoBrid® for burn treatment and EscharEx®, currently in Phase III trials for chronic wound debridement. EscharEx® shows promise for significant market growth, offering advantages over existing treatments. The companys participation in the conference aims to attract investor interest and highlight its innovative products.
Product StageFDA approved/pending approval
growth-positive
MediWound commences Phase III trial for venous leg ulcers treatment
MediWound has initiated a pivotal Phase III VALUE trial to evaluate its bioactive debridement therapy, EscharEx, for venous leg ulcers (VLUs). The trial, involving 216 subjects across 40 European and US sites, aims to assess the therapys safety and efficacy. MediWound has partnered with Solventum, MIMEDX, and Mölnlycke to ensure consistent wound management. An interim analysis is expected in mid-2026. The company is also planning a Phase II trial to compare EscharEx against collagenase and a Phase II/III trial for diabetic foot ulcers. EscharEx has shown promising results in previous Phase II trials.
Product StagePartners
growth-positive
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
MediWound Ltd. has initiated a pivotal Phase III trial, named VALUE, to evaluate the efficacy and safety of EscharEx® for treating venous leg ulcers. This trial is significant as it aims to redefine the standard of care in chronic wound debridement, an area with no new FDA-approved drugs since 1965. The study will involve 216 patients across 40 sites in the U.S. and Europe, with a focus on achieving effective debridement and wound closure. Strategic research collaborations with Solventum, Mölnlycke, and MIMEDX are part of this initiative. An interim analysis is planned for mid-2026. The trials success could position EscharEx as a leader in the $375+ million wound debridement market.
Product StagePartners
growth-positive
MediWound Launches Phase III Trial Evaluating EscharEx for Treating Venous Leg Ulcers
MediWound has announced the initiation of a global Phase III trial for its product EscharEx, aimed at treating venous leg ulcers. This marks a significant step forward in the products development, potentially leading to its approval and commercialization. The trials success could enhance MediWounds market position and expand its treatment offerings. The announcement is seen as a positive development for the company, reflecting its commitment to advancing its product pipeline.
Product Stage
growth-positive
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. CEO Ofer Gonen will engage in a fireside chat, and the management team will host one-on-one meetings with investors. MediWounds NexoBrid® is FDA- and EMA-approved for eschar removal in burns, and its promising candidate EscharEx® is in Phase III development for chronic wound debridement. EscharEx® has shown advantages over existing treatments, indicating significant market growth potential.
Product StageManagement ChangesFDA approved/pending approval
growth-positive
MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week
The article discusses the shareholder composition of MediWound Ltd., highlighting that institutional investors hold a significant portion of the companys stock, with the top 8 shareholders owning 50% of the business. This ownership structure suggests that the stock price might be vulnerable to the trading decisions of these institutions. The article notes a recent 15% gain in the stock price, contributing to a 57% one-year return for shareholders. Clal Life Sciences L.P. is the largest shareholder with 11% of shares, followed by Mölnlycke Health Care AB and Investor AB (publ) with 8.1% each. The companys CEO, Ofer Gonen, holds 1% of the shares. The article emphasizes the potential risks and benefits of institutional ownership.
growth-positive
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?
MediWounds stock rose by 8.5% in the last trading session, driven by positive investor expectations about its product pipeline. The company is developing EscharEx for ulcer treatment, with regulatory approval expected in 2025, and MW005 for non-melanoma skin cancer. MediWound markets NexoBrid, approved for burn treatment in several regions, including the U.S. Despite a projected quarterly loss of $0.61 per share, revenues are expected to rise by 8.6% year-over-year to $5.8 million. The stocks recent performance is attributed to investor optimism about future sales and product development, although earnings estimates have been slightly revised downwards.
Product StageFDA approved/pending approval
growth-positive
Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions
Mediwound has announced significant progress in its product pipeline, emphasizing the commercial potential and market expansion of its key products, NexoBrid and EscharEx. The company is leveraging a strong balance sheet, strategic collaborations, and government contracts to scale operations globally by 2025. With successful clinical trials and substantial funding, Mediwound is poised to challenge existing market players, particularly in the U.S., with its non-surgical burn and wound care solutions. The company operates in the healthcare industry, focusing on enzymatic therapeutics for tissue repair, and has approvals in the US, EU, and Japan. Strategic collaborations, including with BARDA, support its development and commercialization efforts.
Product StagePartnersInvestment
growth-negative
We're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn Rate
The article discusses MediWounds financial situation, focusing on its cash burn rate and cash runway. As of September 2024, MediWound had $46 million in cash with no debt, but its cash burn rate was $22 million over the past year, giving it a cash runway of two years. The company increased its cash burn by 117% while its operating revenue dropped by 21%, raising concerns about its financial trajectory. Despite these challenges, MediWound could potentially raise more cash through issuing shares or taking on debt, though this might lead to shareholder dilution. The article suggests caution for shareholders due to the companys current financial strategy.
growth-positive
MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company’s Future
MediWound Ltd. recently announced that key members of its Board of Directors and the CEO have purchased a total of 18,462 ordinary shares in the open market. These acquisitions, conducted between December 9 and December 13, 2024, demonstrate the leaderships confidence in the companys future prospects and adherence to insider trading policies. This move is likely to bolster stakeholder confidence and might enhance the companys standing in the investment community. MediWound operates in the medical industry, focusing on innovative therapies for burn and wound care, aiming to improve healing in patients with severe injuries.
Investment
growth-positive
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
MediWound Ltd., a leader in enzymatic therapeutics, announced a virtual Key Opinion Leader event on January 8, 2025, focusing on EscharEx®, a biologic drug in late-stage clinical development for chronic wound debridement. The event will highlight the upcoming Phase III VALUE study in venous leg ulcers (VLUs) and EscharEx’s commercial potential. The discussion will include compelling results from Phase II studies, the unmet need for VLUs and diabetic foot ulcers (DFUs), and EscharExs competitive advantages. The event will feature experts like Dr. John C. Lantis II and Dr. Vickie R. Driver. A live Q&A session with MediWounds leadership will follow the presentations.
growth-negative
MediWound Third Quarter 2024 Earnings: Misses Expectations
MediWound reported a revenue of $4.36 million for the latest quarter, marking an 8.8% decline from the previous quarter. The companys net loss widened significantly to $10.3 million, a 368% increase from the last quarter, resulting in a loss of $0.98 per share. Both revenue and earnings per share missed analyst estimates by 27% and 117%, respectively. Despite these setbacks, the companys shares have risen by 7% over the past week. Looking forward, MediWounds revenue is projected to grow at an average annual rate of 44% over the next three years, outpacing the 10% growth forecast for the U.S. pharmaceuticals industry. The article highlights a warning sign for the company but does not specify the details.
growth-negative
MediWound Ltd (MDWD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
MediWound Ltd reported a decline in revenue and gross profit for Q3 2024 compared to the same period in 2023, with revenue dropping to $4.4 million and gross profit to $0.7 million. Despite these financial challenges, the company secured $25 million in strategic funding through a private investment led by Molnlycke Healthcare. MediWound received FDA approval for NexoBrids pediatric use, expanding its market potential in the U.S. The company also completed a new manufacturing facility, expected to increase output sixfold by the end of 2025. However, the anticipated revenue for 2024 was adjusted down due to capacity constraints and reduced BARDA funding. The net loss for the first nine months of 2024 increased significantly to $26.3 million.
InvestmentExpandCustomers
growth-positive
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
MediWound Ltd. announced significant progress in its operations, including FDA approval for pediatric use of its NexoBrid product, which is now authorized for all age groups in the U.S., EU, and Japan. The company is preparing for a Phase 3 trial of EscharEx for venous leg ulcers and is advancing its diabetic foot ulcer program. MediWound has secured $25 million in financing and €16.25 million in EIC funding, strengthening its financial position. The company is expanding its manufacturing capacity with a new facility expected to be fully operational by the end of 2025. NexoBrids demand exceeds current capacity, and its U.S. launch by Vericel is progressing well, with numerous burn centers placing initial orders. The WHOs recognition of enzymatic debridement further supports MediWounds strategic initiatives.
InvestmentCustomersExpand
growth-negative
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
MediWound reported a quarterly loss of $0.98 per share, significantly missing the Zacks Consensus Estimate of a $0.48 loss. This represents an earnings surprise of -104.17%. The company, which develops treatments for burns and hard-to-heal wounds, also reported revenues of $4.36 million, missing the consensus estimate by 27.48%. Despite these misses, MediWound shares have increased by about 70.4% since the beginning of the year, outperforming the S&P 500s gain of 25.5%. The companys future stock performance will depend on managements commentary and earnings outlook. The current consensus EPS estimate for the next quarter is -$0.58 on $7.82 million in revenues. MediWound holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
growth-negative
MediWound: Q3 Earnings Snapshot
MediWound Ltd., based in Yavne, Israel, reported a loss of $10.3 million in its third quarter, translating to a loss of 98 cents per share. This result was below Wall Street expectations, as analysts surveyed by Zacks Investment Research had anticipated a loss of 48 cents per share. The companys revenue for the period was $4.4 million, which also fell short of the $6 million forecasted by analysts. The financial results indicate a challenging quarter for MediWound, as both earnings and revenue did not meet market expectations.
growth-positive
MediWound to Report Third Quarter 2024 Financial Results
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced it will release its third-quarter financial results on November 26, 2024. Following the release, the company will host a conference call and webcast to discuss the results and provide corporate updates. MediWound specializes in non-surgical tissue repair and has developed NexoBrid®, an FDA- and EMA-approved drug for burn treatment. The company is also advancing EscharEx®, a promising candidate in Phase III development for chronic wound debridement. With its proprietary enzymatic technology, MediWound aims to enhance care standards and reduce healthcare costs. The upcoming financial results and updates are expected to highlight the companys growth potential, particularly with EscharExs market opportunities.
growth-positive
MediWound's (NASDAQ:MDWD) investors will be pleased with their stellar 125% return over the last year
MediWound Ltd. has experienced a significant increase in its share price, soaring 125% over the past year despite a 23% decline in revenue. This growth is notable given the companys lack of profitability in the last twelve months. The article suggests that the market may have already priced in the revenue decline, leading to the unexpected share price rise. While the recent performance is positive, the companys five-year annualized total shareholder return (TSR) shows a loss of 3% per year, indicating potential long-term challenges. The article emphasizes the importance of considering market conditions and other factors when evaluating the companys performance.
growth-positive
Rosalind Advisors, Inc. Increases Stake in MediWound Ltd
On September 30, 2024, Rosalind Advisors, Inc., a prominent investment firm, expanded its portfolio by acquiring an additional 114,560 shares of MediWound Ltd. This acquisition increased the firms total holdings in the company to 628,050 shares, representing 8.59% of its portfolio. The shares were purchased at $18.06 each, indicating a strategic move to strengthen its position in the biotechnology sector. MediWound Ltd, an Israeli biopharmaceutical company, focuses on developing therapeutic products for severe burns and chronic wounds. Despite a challenging financial performance and a current market capitalization of $181.104 million, the company shows potential for growth. The acquisition reflects Rosalind Advisors confidence in MediWounds future prospects, despite its current valuation challenges.
Investment
growth-positive
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
MediWound Ltd. announced new R&D collaborations with Solventum and Mölnlycke to support a Phase II clinical study of EscharEx for treating venous leg ulcers. The study aims to support the Biologics License Application (BLA) for EscharEx and strengthen the companys commercialization strategy. The trial will involve 45 patients across the U.S. and Europe, comparing EscharEx to collagenase ointment. The partnerships with Solventum and Mölnlycke are designed to enhance trial consistency and patient outcomes. MediWound is a leader in enzymatic therapeutics, with EscharEx showing promise in previous trials. The study is part of MediWounds broader strategy to expand its market presence.
Partners
growth-positive
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, announced that CEO Ofer Gonen will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. The event is scheduled for October 16, 2024, and will be hosted by Michael Okunewitch, a Senior Biotechnology Analyst at Maxim. MediWound is known for its FDA and EMA-approved drug NexoBrid®, used for eschar removal in severe burns, and is advancing EscharEx®, a candidate for chronic wound debridement. The company aims to expand its market presence with EscharEx, which offers advantages over the current market leader. The management team will also be available for one-on-one meetings with interested investors during the summit.
growth-positive
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MediWound Ltd., a leader in next-generation enzymatic therapeutics for tissue repair, announced that its CEO, Ofer Gonen, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. The event will be hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research. MediWound specializes in developing biologics for non-surgical tissue repair, including its FDA and EMA-approved drug NexoBrid® for burn treatment and its Phase III-ready drug EscharEx® for chronic wound debridement. The company aims to improve patient care and reduce costs through its innovative products.
Public Trading
Neutral
MediWound Ltd.'s (NASDAQ:MDWD) top owners are retail investors with 38% stake, while 28% is held by institutions
MediWound Ltd. is a company with a significant ownership by retail investors, who collectively hold 38% of the company. Institutional investors own 28% of the company, with Clal Life Sciences L.P. being the largest shareholder with 11% of shares. The top 13 shareholders control 51% of the ownership. Private equity firms hold a 10% stake, and private companies hold 19%. The companys CEO, Ofer Gonen, owns 1.0% of the companys shares.
Investment
growth-positive
MediWound and Vericel win FDA paediatric label expansion for NexoBrid
MediWound and Vericel Corporations thermal burn treatment, NexoBrid, has received approval from the US Food and Drug Administration (FDA) for use in paediatric patients with severe burns. The approval builds on a previous one for the same indication in adults. NexoBrid, a gel consisting of proteolytic enzymes, was developed by MediWound, with Vericel acquiring commercialisation rights in North America in 2019. The product generated $19m in sales in 2023, and is expected to generate over $98m by 2030. MediWound is also developing another proteolytic enzyme gel, EscharEx, for treating venous leg ulcers and diabetic foot ulcers.
CustomersPartners
growth-positive
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
MediWound Ltd. has received FDA approval for a pediatric indication for NexoBrid, a non-surgical burn treatment. This approval allows for eschar removal in pediatric patients aged newborn through eighteen with deep partial- and/or full-thickness thermal burns. The approval aligns with NexoBrids approvals in the European Union and Japan. The submission was supported by the results of a global Phase III clinical trial, Children Innovation Debridement Study (CIDS), which evaluated the safety and efficacy of NexoBrid in hospitalized pediatric patients. The CIDS trial was funded by the Biomedical Advanced Research and Development Authority (BARDA).
CustomersPartners
growth-negative
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
MediWound reported a quarterly loss of $0.68 per share, which is significantly higher than the Zacks Consensus Estimate of a loss of $0.42. This is a stark contrast to the earnings of $0.10 per share reported a year ago. The companys revenues for the quarter ending June 2024 were $5.06 million, missing the Zacks Consensus Estimate by 0.18%. Despite the disappointing results, MediWounds shares have increased by about 79.1% since the beginning of the year. The companys future performance will largely depend on managements commentary on the earnings call.
Investment
growth-negative
MediWound: Q2 Earnings Snapshot
MediWound Ltd. reported a loss of $6.3 million in its second quarter, falling short of Wall Street expectations. The Yavne, Israel-based company, which develops treatments for burns and hard-to-heal wounds, posted revenue of $5.1 million in the period, matching Street forecasts.
Investment
growth-positive
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
MediWound Ltd. has announced its Q2 2024 financial results and provided a corporate update. The company completed the construction of a new manufacturing facility for NexoBrid® and secured €16.25 million in funding from the European Innovation Council (EIC) to expand EscharEx’s indications to include diabetic foot ulcers. Furthermore, MediWound raised $25 million in financing led by Mölnlycke Health Care. The companys revenue for Q2 2024 was $5.1 million, up from $4.8 million in the same period of 2023. However, the company reported a net loss of $6.3 million for Q2 2024.
InvestmentExpand
growth-positive
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) reported a quarterly loss of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.25. This is an improvement from a loss of $0.02 per share a year ago. The pharmaceutical and drug compounding company posted revenues of $48.94 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 14.40%. This compares to year-ago revenues of $33.47 million. Harrow shares have added about 102.9% since the beginning of the year. The companys earnings outlook is favorable, with the current consensus EPS estimate being -$0.13 on $49.42 million in revenues for the coming quarter.
Investment
growth-positive
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
MediWound is expected to report a year-over-year decline in earnings on higher revenues for the quarter ended June 2024. The earnings report, due to be released on August 14, 2024, could impact the companys stock price depending on how the actual results compare to estimates. The consensus EPS estimate for the quarter has been revised 3.52% higher over the last 30 days. The companys Earnings ESP is +4.76%, indicating a likely earnings beat. The stock currently carries a Zacks Rank of #2, further suggesting a positive earnings surprise.
Investment
growth-positive
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
MediWound Ltd. has announced positive results from the NEXT protocol, a program initiated in 2019 to ensure the continuous availability of NexoBrid, a treatment for burn victims, in burn centers until its commercialization. The program was successful in maintaining physician expertise, providing burn victims with ongoing access to the treatment, and facilitating the accumulation of real-world safety and clinical data for NexoBrid. The results from the NEXT protocol reaffirm the significant benefits of NexoBrid in managing severe burns, reducing the need for surgical interventions and enhancing patient outcomes.
CustomersPartners
growth-positive
MediWound to Report Second Quarter 2024 Financial Results
MediWound Ltd., a global leader in next-generation enzymatic therapeutics for tissue repair, has announced that it will release its financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024. Following the release, management will host a conference call and live webcast to discuss the financial results, provide corporate updates, and answer questions. The companys first drug, NexoBrid, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns. The company is also developing EscharEx, a Phase III-ready biologic for the debridement of chronic wounds.
Investment
growth-positive
Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?
MediWounds stock closed at $18.89, marking a 21.4% gain over the past four weeks. Wall Street analysts mean price target of $29.75 indicates a potential 57.5% upside. The average comprises four short-term price targets ranging from $25 to $36. The companys ability to report better earnings than predicted earlier strengthens this view. However, investors are advised to treat price targets with skepticism due to potential bias among analysts. Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 3.6%, and MediWound currently has a Zacks Rank #2 (Buy).
Investment
growth-positive
MediWound reinforces wound therapy EscharEx data ahead of Phase III trial
MediWound has published positive Phase II trial data for its wound debridement therapy, EscharEx, showing its superiority in treating venous leg ulcers compared to other non-surgical standard-of-care solutions. The trial enrolled 119 patients, with 63% of those who received EscharEx achieving complete debridement, compared to 30.2% and 13.3% in the placebo and non-surgical standard of care treatments respectively. The company plans to start a Phase III trial evaluating EscharEx as a treatment for venous leg ulcers in the second half of this year.
Customers
growth-positive
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
MediWound Ltd. has announced the publication of a peer-reviewed study on the Phase II ChronEx study assessing the safety and efficacy of EscharEx for the treatment of Venous Leg Ulcers (VLU) in eClinicalMedicine, a journal under THE LANCET Discovery Science umbrella. The study was conducted across 20 medical centers and clinics in the United States, Europe, and Israel. The results showed that EscharEx outperformed the non-surgical standard of care in debridement and promotion of healthy granulation tissue. The company is set to initiate a Phase III study for Venous Leg Ulcers in the second half of 2024.
InvestmentExpand
growth-positive
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
MediWound Ltd. has been selected to receive €16.25 million in blended funding from the European Innovation Council (EIC) through its accelerator program. The funding will be used to advance the companys EscharEx development program for patients with diabetic foot ulcers (DFUs). The funding will enable the company to expedite the market introduction of EscharEx, potentially four years ahead of the original schedule. The EIC Accelerator offers grants and equity investments to support innovative products. The funding package includes a €2.5 million grant and an investment.
Investment
growth-positive
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
Mölnlycke Health Care, a MedTech company specialising in wound care and surgical procedures, has announced a $15m investment in MediWound Ltd. MediWound is a global leader in next-generation enzymatic therapeutics focused on non-surgical wound debridement. The investment aligns with Mölnlyckes strategy to bring innovations into the wound care space and provide alternative solutions to traditional debridement options. Mölnlycke and MediWound have also entered into a collaboration agreement to strengthen their partnership.
InvestmentPartners
growth-positive
MediWound Announces $25 Million Strategic Private Placement Financing
MediWound Ltd. has announced a definitive share purchase agreement with several new and existing investors, including Mölnlycke Health Care, which leads the PIPE with a $15 million investment. The agreement includes the sale and purchase of 1,453,488 shares of MediWound at $17.20 per share, with gross proceeds from the PIPE Offering amounting to $25 million. The funds will be used to advance EscharEx pre-commercial activities, expedite the development of large-scale manufacturing capabilities for EscharEx, and support general corporate purposes. MediWound and Mölnlycke have also entered into a collaboration agreement to strengthen their partnership.
InvestmentPartners
growth-negative
Is MediWound (NASDAQ:MDWD) In A Good Position To Invest In Growth?
MediWound, a biotech company, is facing concerns over its cash burn rate. The companys cash burn has increased by 142% over the past year, indicating heavy investment in the business. However, its operating revenue has dropped by 23%, causing concern for its future growth. As of March 2024, MediWound had a cash reserve of $36m and a cash burn of $22m, giving it a cash runway of approximately 19 months. The companys cash burn relative to its market cap is not seen as problematic, but the increasing cash burn rate is a cause for concern.
Investment
growth-positive
MediWound jumps on reports of $400m bid by Solventum
Israeli biopharmaceutical company MediWounds share price jumped 35% after reports that US company Solventum had offered to acquire it for $400 million. MediWound, which has developed a pineapple-plant based product for treatment of burns and wounds, saw its market cap rise to $182 million. The company has made no official comments on the reports of Solventums offer.
Acquisition
growth-positive
MediWound jumps on reports of $400m bid by Solventum
MediWound, an Israeli biopharmaceutical company known for its pineapple-plant based treatment for burns and wounds, experienced a significant increase in its share price, rising 35% to $19.60, following reports of a potential acquisition by US company Solventum. Solventum has reportedly offered $400 million, or $34 per share, to acquire MediWound. Despite the surge, MediWounds share price remains below its 2021 peak. The company, led by CEO Ofer Gonen, has not officially commented on the acquisition reports, and market sources suggest that negotiations are still in the early stages. The companys market cap is currently $182 million.
Acquired-by
Growth-Negative
Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
MediWound Ltd. reported its latest quarterly results, with revenues of $5.0m beating expectations by 6.3%. However, the companys losses per share increased to $1.05, 158% more than what analysts had predicted. Analysts are now predicting revenues of $23.8m in 2024, a 20% improvement compared to the last 12 months. However, losses are forecast to increase 89% to $2.60 per share. The consensus price target for MediWounds stock remains steady at $28.50.
Investment
growth-positive
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
MediWound Ltd. has reported a surge in interest for its NexoBrid product, with Q1 2024 revenue reaching $5 million and a forecast of $24 million for the year. The companys manufacturing facility is expected to be completed by mid-2024. The EscharEx Phase III study is set to launch in 2H 2024. The company is also set to join the Russell 3000 Index. More than 60 burn centers have completed submissions for NexoBrid, with around 40 centers obtaining approval and over 30 centers placing initial product orders. The companys new manufacturing facility is on track to be completed by mid-2024 and is expected to be fully operational in 2025.
CustomersPartnersExpand
Growth-Positive
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
MediWound reported a quarterly loss of $0.39 per share, beating the Zacks Consensus Estimate of a loss of $0.40. This is an improvement from a loss of $0.44 per share a year ago. The company, which develops treatments for burns and hard-to-heal wounds, posted revenues of $4.96 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 6.82%. This is an increase from year-ago revenues of $3.8 million. MediWound shares have increased by about 74.9% since the beginning of the year. The companys future performance will depend on managements commentary on the earnings call and earnings outlook.
Investment
Neutral
MediWound to Report First Quarter 2024 Financial Results
MediWound Ltd., a global leader in next-generation enzymatic therapeutics for tissue repair, has announced that it will release its financial results for the first quarter ended March 31, 2024 on Wednesday, May 29, 2024. Following the release, the companys management will host a conference call and live webcast to discuss the financial results, provide corporate updates, and answer questions. The companys first drug, NexoBrid, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns. The company is also developing EscharEx, a Phase III-ready biologic for the debridement of chronic wounds.
Growth-Positive
Investors in MediWound (NASDAQ:MDWD) have seen decent returns of 65% over the past year
MediWound Ltd.s share price has risen by 65% in the last year, outperforming the market return of around 26%. However, the companys long-term returns have not been as promising, with the stock falling 33% in the last three years. Despite this, the market sentiment around the stock is improving. MediWounds revenue has shrunk by 29% in the last year, but this has not prevented the stocks impressive performance. The company was not profitable in the last twelve months.
Customers
growth-positive
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
MediWound Ltd. has announced that recent clinical data from EscharEx Phase II studies will be presented at the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC) throughout May 2024. The data indicates that EscharEx could significantly improve wound care for patients with chronic wounds, providing significant benefits over the current standard of care. The findings also support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024.
InvestmentExpand
growth-positive
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
MediWounds shares rose by 14.3% in the last trading session, closing at $18.28. This increase was supported by a higher than usual volume of shares traded. The company recently announced strong financial results for the full year and fourth quarter of 2023, which may have contributed to the share price rally. Despite a predicted quarterly loss of $0.40 per share in its upcoming report, revenues are expected to be $4.65 million, a 22.3% increase from the same quarter last year. However, the consensus EPS estimate for the quarter has been revised 8.2% lower over the last 30 days.
Customers
growth-positive
Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
Shares of MediWound (MDWD) have seen a 19.2% increase over the past four weeks, closing at $15.97. Wall Street analysts predict further growth, with a mean estimate of $28.25, indicating a potential upside of 76.9%. However, the article cautions against relying solely on these predictions, as analysts ability to set accurate price targets has been questioned. The article suggests that the strong agreement among analysts about MediWounds ability to report better earnings than predicted could be a more reliable indicator of potential growth. The Zacks Consensus Estimate for the current year has increased 9.3% over the past month.
Public Trading
growth-positive
What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
MediWound (MDWD) is identified as a solid choice for trend investing due to its recent price strength and sound fundamentals. The stock has gained 57% over a period of 12 weeks, reflecting investors continued willingness to pay more for the potential upside. The stock currently carries a Zacks Rank #2 (Buy), indicating it is in the top 20% of more than 4,000 stocks ranked based on trends in earnings estimate revisions and EPS surprises. The companys Average Broker Recommendation of #1 (Strong Buy) also confirms its fundamental strength.
Investment
Growth-Positive
MediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
MediWound Ltd. recently reported its full-year numbers, with revenues of $19m in line with analyst predictions and losses 6% smaller than expected. Analysts predict revenues of $24.0m in 2024, a 29% improvement compared to the last 12 months. However, per-share losses are expected to increase. The consensus price target remains at $28.50. MediWounds rate of growth is expected to accelerate, with the forecast 29% annualised revenue growth to the end of 2024 faster than its historical growth of 6.3% p.a. over the past five years.
Investment
growth-positive
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound reported a quarterly loss of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.23. This is an improvement from a loss of $1.18 per share a year ago. The company, which develops treatments for burns and hard-to-heal wounds, posted revenues of $5.34 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 0.21%. This compares to year-ago revenues of $11.62 million. The companys shares have added about 53.6% since the beginning of the year.
Investment
growth-positive
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
MediWound Ltd. has announced its financial results for the fourth quarter and full year ended December 31, 2023. The company reported $19 million revenue in 2023 and projected $24 million revenue in 2024. The companys product, NexoBrid, was commercially launched in the U.S., Japan, and India. The company also received substantial new governmental grants and saw increased global demand for NexoBrid. The companys other product, EscharEx, is set to begin Phase III in the second half of 2024. The company also reported a cash runway of $42 million through profitability.
CustomersPartnersInvestment
Growth-Positive
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
MediWound Ltd., a global leader in next-generation enzymatic therapeutics for tissue repair, will release its financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024. Following the release, the companys management will host a conference call and live webcast to discuss the financial results, provide corporate updates, and answer questions. The companys first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns. MediWound is also developing EscharEx®, a Phase III-ready biologic for debridement of chronic wounds, and MW005, a topical therapeutic for the treatment of basal cell carcinoma.
growth-positive
Retail investors who hold 38% of MediWound Ltd. (NASDAQ:MDWD) gained 15%, institutions profited as well
MediWound Ltd.s ownership structure is significantly influenced by retail investors who hold around 38% of the companys shares. Institutional investors hold 16% of the companys shares, while hedge funds own 14%. The largest shareholder is Clal Life Sciences L.P. with 13% of shares. The second and third largest shareholders hold 8.9% and 6.0% of the shares, respectively. Private equity firms hold a 12% stake, and private companies hold 13%. Insiders own shares worth US$10m. The article suggests that this diverse ownership structure balances out interests and holds management accountable.
Investment
growth-positive
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
Shares of MediWound (MDWD) increased by 7.1% in the last trading session, closing at $15.42. This surge was supported by a higher than usual volume of shares traded. The companys stock has gained 28% over the past four weeks. Last month, MediWound announced data from a comparison analysis of its lead asset, EscharEx, with collagenase Santyl ointment. The data showed that EscharEx was superior to Santyl in treating patients with chronic venous leg ulcers, which may have contributed to the stocks rally. The company is expected to post a quarterly loss of $0.23 per share in its upcoming report, a year-over-year change of +80.5%.
Customers
growth-positive
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
MediWound Ltd. has announced the results of a head-to-head comparison of its lead asset, EscharEx, with collagenase SANTYL ointment, a market-leading enzymatic debridement product. The results demonstrated the superiority of EscharEx in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers. The CEO of MediWound, Ofer Gonen, stated that these results position EscharEx to become the market leader in enzymatic agents for the treatment of chronic wounds. The company plans to begin a Phase III trial in the second half of 2024.
CustomersExpand
Growth-Positive
MediWound to Participate in Two Upcoming Investor Conferences
MediWound Ltd., a biopharmaceutical company, has announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference and the TD Cowen 44th Annual Health Care Conference. The companys management team will host one-on-one meetings during both conferences. MediWound is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The companys first drug, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns. The companys pipeline also includes EscharEx, a Phase III-ready biologic for debridement of chronic wounds, and MW005, a topical therapeutic for the treatment of basal cell carcinoma.
Investment
growth-positive
Here's Why We're Not Too Worried About MediWound's (NASDAQ:MDWD) Cash Burn Situation
MediWound, a NASDAQ listed company, is in a good position in terms of managing its cash burn, according to an analysis by Simply Wall St. The company had a cash runway of about 4.4 years from September 2023, which is considered reassuringly long. MediWound managed to reduce its cash burn by 38% over the last year, and its operating revenue gained 23% during that period. The companys cash burn equates to about 8.7% of its market value, indicating that it could easily fund another years growth by issuing new shares or taking out a loan.
Investment
growth-positive
MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross
MediWound Ltd. (MDWD) has reached a significant support level, indicating it could be a good stock pick from a technical perspective. The company recently experienced a golden cross event, a bullish breakout signifier, where its 50-day simple moving average broke out above its 200-day simple moving average. This pattern suggests a positive trend reversal and potential for higher prices. Over the past four weeks, MDWD has rallied 20.1% and is currently ranked as a #2 (Buy) on the Zacks Rank. The companys earnings expectations also support the bullish uptrend, with 3 changes higher compared to none lower over the past 60 days.
growth-positive
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
MediWound Ltd., a biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted a supplement to the NexoBrid® biologics license application for the removal of eschar in pediatric patients with deep partial- and/or full-thickness thermal burns. NexoBrid is already approved for use in adult patients in the U.S., Europe, and Japan. The supplement seeks to expand the label for NexoBrid to include both adult and pediatric burn patients of all ages. The acceptance of the NexoBrid sBLA filing by the FDA is an important milestone for MediWound.
CustomersPartners
growth-positive
MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
MediWound Ltd. is currently an attractive choice for investors, according to Zacks Investment Research. The company, which operates in the Medical - Drugs space, has seen solid earnings estimate revision activity, suggesting a growing bullish sentiment among analysts. The Medical - Drugs industry is also performing well, with a Zacks Industry Rank of 76 out of more than 250 industries. Over the past month, MediWounds current quarter estimates have improved, and the company has earned a Zacks Rank #2 (Buy).
Investment
growth-positive
Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
Shares of MediWound (MDWD) have seen a 14.4% increase over the past four weeks, closing the last trading session at $11.82. However, Wall Street analysts predict a potential upside of 134.8%, with a mean estimate of $27.75. Despite the consensus price target being a sought-after metric for investors, it is not always a reliable indicator of a stocks potential gain. Analysts have shown increasing optimism about MediWounds earnings prospects, with strong agreement in revising EPS estimates higher. The company currently has a Zacks Rank #2 (Buy), indicating potential upside in the near term.
Public Trading
growth-positive
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
MediWound Ltd., a biopharmaceutical company, has been awarded an additional $6.7 million by the U.S. Department of Defense (DoD) through the Medical Technology Enterprise Consortium (MTEC) to develop NexoBrid, a non-surgical solution for field-care burn treatment for the U.S. Army. This increases the project budget to $14.4 million. The funding will be used to advance the development and production of a new, temperature-stable formulation of NexoBrid. Vericel Corporation holds an exclusive license for the commercial and development rights to NexoBrid in North America.
InvestmentPartners
Growth-Positive
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
MediWound Ltd. has announced the publication of a peer-reviewed paper detailing the results of a Phase II study on EscharEx, an enzymatic debridement agent. The study found that EscharEx not only effectively debrides wounds, but also reduces biofilm and bacterial load in both venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). The company plans to initiate a Phase III pivotal study in the second half of 2024. MediWound is a global leader in next-generation enzymatic therapeutics for tissue repair.
InvestmentExpand
growth-negative
MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
MediWound Ltd. has seen a 26% gain in share price over the past month, recovering from previous weakness. However, the companys price-to-sales (P/S) ratio of 3.9x is higher than the average for the wider Pharmaceuticals industry in the United States. Despite a 23% increase in revenue over the past year, MediWounds revenue growth is less than most other companies, which could be a reason for the high P/S ratio. Analysts predict that the companys revenue should grow by 31% per annum over the next three years, which is less than the industry forecast of 53% per year.
Public Trading
growth-positive
Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to Trade
Shares of MediWound (MDWD) have seen a 33.1% increase over the past four weeks, closing the last trading session at $10.21. However, Wall Street analysts short-term price targets suggest there could still be significant growth potential in the stock, with a mean estimate of $27.75 indicating a potential upside of 171.8%. The companys earnings prospects have also been revised upwards, with the Zacks Consensus Estimate increasing by 34.8%. MediWound currently has a Zacks Rank #2 (Buy), indicating potential for further growth.
growth-negative
MediWound (NASDAQ:MDWD) investors are sitting on a loss of 75% if they invested five years ago
MediWound Ltd.s share price has gained 14% in the last three months, despite a 75% decline over the last five years. The companys revenue has increased by 12% per year over the last half decade, but it has not been profitable in the last twelve months. The market has been harsh on the company, with the stock down 12% per year in the last five years. MediWound shareholders are down 9.7% for the year, while the market itself is up 16%. The company has been identified with 2 warning signs, at least one of which cannot be ignored.
Public Trading
growth-positive
Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?
Shares of MediWound (MDWD) have increased by 10.6% over the past four weeks, closing at $8.59. However, Wall Street analysts predict further growth, with a mean estimate of $27.75, indicating a potential upside of 223.1%. Despite the potential for bias in these estimates, the strong agreement among analysts about MediWounds ability to exceed earnings predictions strengthens the view of potential growth. Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 12.4%, and MediWound currently has a Zacks Rank #2 (Buy), indicating potential near-term upside.
Investment
growth-positive
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
MediWound Ltd., a biopharmaceutical company, has announced the appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer effective from December 1, 2023. Dr. Hess will oversee all operational and commercial activities at MediWound. He has over two decades of experience in drug development and commercial operations in healthcare. Prior to joining MediWound, he served as CEO at Tabby Therapeutics, Enlivex Therapeutics, and Valin Technologies. He was also a global operations executive at SciGen Ltd. MediWound is focused on non-surgical tissue repair and has developed a strong R&D pipeline including NexoBrid® and EscharEx®.
Management ChangesExpand
growth-positive
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
MediWound Ltd. has announced its Q3 2023 financial results, revealing a net loss of $2.2 million. Despite this, the company has seen significant growth, with the successful launch of NexoBrid® in the U.S. and Japan. The company has also secured $6.5 million in R&D funding from the U.S. Department of Defense and has established partnerships with PolyMedics Innovations, Vericel Corporation, and Kaken Pharmaceutical Co. The company has also appointed Shmulik Hess as the Chief Operating Officer and Chief Commercial Officer, effective from December 1, 2023.
CustomersPartnersInvestmentManagement ChangesExpand
growth-positive
MediWound to Report Third Quarter 2023 Financial Results
MediWound Ltd., a global leader in next-generation enzymatic therapeutics for tissue repair, will release its financial results for the third quarter ended September 30, 2023, on Tuesday, November 21, 2023. Following the release, the companys management will host a conference call and live webcast to discuss the financial results, provide corporate updates, and answer questions. The companys first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns. MediWound is also developing EscharEx®, a Phase III-ready biologic for debridement of chronic wounds.
Management Changes
growth-positive
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
MediWound Ltd. has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to expand the marketing authorization for NexoBrid, a non-surgical treatment for burn patients, to include all age groups. This decision is based on the results of a global Phase 3 trial that evaluated the safety and efficacy of NexoBrid in hospitalized pediatric patients. The study met its three primary endpoints with a high degree of statistical significance. The CEO of MediWound, Ofer Gonen, stated that this milestone advances their goal to redefine the standard of care for the treatment of severe burns.
CustomersExpand
growth-positive
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
MediWound Ltd. and PolyMedics Innovations (PMI) have announced a partnership to promote NexoBrid, a non-surgical solution for eschar removal in burns, in Germany, Austria, Belgium, the Netherlands, and Luxemburg. The partnership will leverage PMIs extensive customer access and commercial resources to increase the utilization of NexoBrid in these regions. The collaboration is expected to bring NexoBrid to a broader audience of burn surgeons and improve patient care. NexoBrid is approved in over 40 countries, including the United States, European Union, and Japan.
PartnersExpand
growth-positive
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
MediWound Ltd. has announced a collaboration with 3M Health Care for a pivotal study on patients with venous leg ulcers. 3M Health Care will provide its Coban 2 and Coban 2 Lite two-layer compression systems for use during the debridement and wound healing phases of the EscharEx Phase III study. The study aims to evaluate the efficacy and safety of EscharEx in the debridement of chronic wounds. The compression systems will be used as standard care in all study arms until the wounds reach complete healing.
Partners
growth-positive
MediWound Deploys NexoBrid® for Emergency Supply
MediWound Ltd., a biopharmaceutical company, is addressing the emergency demand for its product NexoBrid, used to treat burn casualties, amidst the war in Israel. Hospitals and military forces have urgently requested supplies of NexoBrid. In response, MediWound has deployed all its available inventory to aid the substantial number of burn victims. The company remains committed to fulfilling its obligations to global markets and is implementing measures to ensure supply continuity. NexoBrid is approved in over 40 countries, including the United States, European Union, and Japan.
Customers
growth-positive
Q4 Stock Predictions: 3 Micro-Cap Stocks Ready to Skyrocket Into 2024
Jeremy Siegel’s prediction that the Federal Reserve will not raise interest rates in November has led to the emergence of micro-cap stocks to buy. The absence of interest rate hikes keeps borrowing costs low, facilitating capital access for these small companies to invest in growth. This article highlights three micro-cap stocks with great upside potential: Ceragon Networks, MediWound, and Travelzoo. Ceragon Networks has signed a multi-year contract with African telecommunication company Paratus and a partnership with Indian telecommunication company Airtel. MediWound secured $6.5 million in funding from the United States Department of Defense. Travelzoo has been innovating with a metaverse initiative, offering customers a virtual travel experience.
InvestmentPartners
Growth-Positive
MediWound Ltd. (NASDAQ:MDWD) surges 19%; individual investors who own 46% shares profited along with institutions
MediWound Ltd. has significant control by individual investors, who hold around 46% of shares, implying that the general public has more power to influence management and governance-related decisions. A total of 17 investors have a majority stake in the company with 51% ownership. Institutional ownership in MediWound is 26%. The largest shareholder is Clal Life Sciences L.P. with 12% of shares outstanding. The second and third largest shareholders hold about 8.7% and 4.3% of the stock respectively. Insiders collectively own US$7.1m worth of the US$103m company.
Investment
growth-positive
MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?
Shares of MediWound, a developer of treatments for burns and hard-to-heal wounds, soared 18.2% in the last trading session, marking the third consecutive day of price increase. This follows the announcement that the U.S. Department of Defense has awarded additional funding to the company for the development of NexoBrid, a non-surgical solution for field-care burn treatment for the U.S. Army. Despite expectations of a quarterly loss of $0.43 per share and revenues of $4.82 million (down 17% from the year-ago quarter), the stocks price has continued to rise.
Investment
growth-positive
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
MediWound Ltd. has received an additional $6.5 million in funding from the U.S. Department of Defense (DoD) and the Medical Technology Enterprise Consortium (MTEC) to develop NexoBrid, a non-surgical solution for field-care burn treatment for the U.S. Army. The funding will be used to develop a new, temperature stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings. The MTEC Research Project Award was granted by the DoD’s U.S. Army Medical Research and Development Command (USAMRDC) and funded by the Defense Health Agency through MTEC.
InvestmentPartners
growth-positive
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
MediWound Ltd., a biopharmaceutical company, has announced the commercial availability of NexoBrid, a product for the removal of eschar in adults with deep partial and/or full-thickness thermal burns. The product selectively targets eschar while preserving viable tissue, potentially reducing the need for skin grafting and lessening patient trauma. The product is now available in the United States through MediWounds partner, Vericel. The company sees a $300 million addressable market for NexoBrid in the U.S., where each year approximately 40,000 people are hospitalized for burn-related injuries, and more than 30,000 of them require some level of eschar removal.
CustomersPartnersExpand
Growth-Positive
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
MediWound Ltd., a biopharmaceutical company, announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference taking place in New York City and virtually from September 11-13, 2023. The companys CEO, Ofer Gonen, will participate in a fireside chat hosted by Swayampakula Ramakanth, Managing Director of Equity Research. The MediWound management team will also host one-on-one meetings during the conference. MediWound is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair.
Investment
growth-positive
Here's Why We're Not Too Worried About MediWound's (NASDAQ:MDWD) Cash Burn Situation
The article discusses the cash burn situation of MediWound, a company listed on NASDAQ. It analyzes the companys cash reserves and cash runway, indicating that it has a cash runway of about 5.1 years. The article also highlights that MediWound has reduced its cash burn by 33% and experienced a 24% increase in operating revenue. It mentions that the company could raise more cash for growth without much trouble, although it may result in some dilution. Overall, the article suggests that shareholders should not be worried about MediWounds cash burn situation. It also mentions three warning signs for the company. The date of the event described in the article is not provided.
Investment
growth-positive
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
MediWound Ltd. has announced its financial results for Q2 2023, revealing significant progress on many levels. The companys EscharEx Phase III study protocol is aligned with feedback from both FDA and EMA, and patient enrollment is planned for early 2024. The company has also secured research and development collaborations with leading wound care companies, MIMEDX and Mölnlycke. Additionally, MediWound has been awarded an additional $10 million in funding from BARDA. The companys cash and short-term deposits as of June 30, 2023, were $51.3 million.
InvestmentPartnersManagement ChangesExpand
growth-positive
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
MediWound has entered into a research collaboration agreement with MIMEDX Group to use its placental tissue allograft EPIFIX in the Phase III study of EscharEx for venous leg ulcers. The collaboration aims to maintain consistency and optimize healing outcomes for study subjects. EscharEx is a topical biologic drug that enzymatically removes nonviable wound tissue. The study will evaluate its efficacy and safety in debriding chronic wounds in venous leg ulcers. The collaboration is seen as a significant milestone in the wound care field, as there have been no new FDA-approved drugs in this category since 1997.
Partners
growth-positive
MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates
MediWound reported quarterly earnings of $0.10 per share, beating expectations. The companys revenues for the quarter also exceeded estimates. However, MediWound shares have lost about 33.9% since the beginning of the year. The companys earnings outlook is unfavorable, resulting in a Zacks Rank #4 (Sell) for the stock. The industry outlook for Medical - Drugs is positive. Akebia Therapeutics, another company in the same industry, is expected to report quarterly results soon.
Customers
growth-positive
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
MediWound Ltd. has announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study of EscharEx® in venous leg ulcers. Mölnlycke will provide dressings to be used during the wound healing phase of the study. The collaboration aims to reduce variability and achieve the trials endpoints. Mölnlyckes dressings will be used as the standard of care in all study arms. EscharEx is a topical biologic drug being evaluated for efficacy and safety in the debridement of chronic wounds. The Phase III study is set to begin in early 2024. Mölnlycke is a world-leading medical products and solutions company. The collaboration is expected to have a positive impact on MediWounds growth.
Partners
Growth-Positive
MediWound to Report Second Quarter 2023 Financial Results
MediWound Ltd., a global leader in next-generation enzymatic therapeutics for tissue repair, has announced that it will release its financial results for the second quarter ended June 30, 2023, on Tuesday, August 15, 2023. Following the release, the companys management will host a conference call and live webcast to discuss the financial results, provide corporate updates, and answer questions. The companys first drug, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns. The companys pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma.
Customers
growth-positive
MediWound Announces Commercial Launch of NexoBrid® in Japan
MediWound Ltd., a biopharmaceutical company, has announced the launch of NexoBrid in Japan for the treatment of deep partial thickness and full thickness burns in adults and pediatric patients. The launch is in partnership with Kaken Pharmaceutical Co. Ltd, which holds the exclusive marketing and distribution rights for NexoBrid in Japan. NexoBrid is a non-surgical treatment option for burn patients, replacing the current standard of care which is based on non-selective, expensive, and potentially disfiguring surgical excisions. The launch of NexoBrid in Japan is expected to benefit over 6,000 patients treated for severe burns annually.
PartnersExpand
Growth-Positive
3 Micro-Cap Stocks to Buy for Multibagger Returns
The article discusses the potential of three micro-cap stocks, Yatra Online, MediWound, and StealthGas, to provide multibagger returns. Yatra Online, an online travel company with a strong presence in India, is expected to benefit from the acceleration of business travel and the growing middle class. MediWound, a company focused on non-surgical tissue repair, has a potential addressable market of over $3 billion across its therapies. StealthGas, a provider of seaborne transportation services to liquified petroleum gas producers and users, is undervalued with a forward price-earnings ratio of 4.3 and is expected to continue delivering strong numbers.
Investment
growth-positive
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MediWound Ltd., a biopharmaceutical company, has announced positive data from its Phase I/II study evaluating the safety and efficacy of MW005 in treating low-risk Basal Cell Carcinoma (BCC). The data showed MW005 to be safe and well-tolerated, with patients achieving complete clearance of their target lesions. Fifteen patients were treated with MW005 and completed the study. Eleven out of fifteen patients achieved complete clearance of their BCCs. The results will be featured at an upcoming scientific conference in 2023.
InvestmentExpand
growth-positive
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
MediWound Ltd. has received positive scientific advice from the European Medicines Agency (EMA) regarding the development plan for its Phase III study of EscharEx in the treatment of Venous Leg Ulcers (VLUs). The CHMP concurs with the overall design of the study and can accept one confirmatory study as the basis for approval. EscharEx addresses an important medical need for patients suffering from chronic wounds. The Phase III study will be a global, multi-center, prospective, randomized, placebo-controlled trial in approximately 244 patients. VLUs affect approximately 560,000 patients annually with an estimated $1 billion market in the U.S. alone. EscharEx uses the same active pharmaceutical ingredient as NexoBrid, which has been approved for debridement of thermal burns in the U.S. and Europe.
Customers
growth-negative
MediWound (NASDAQ:MDWD) shareholders have endured a 79% loss from investing in the stock five years ago
The article discusses the poor stock performance of MediWound Ltd. over the past five years, with a 79% decline in share price. The stock is also down 21% in the last year and about a quarter. Despite the companys revenue growth of 21% per year, the share price has not reflected this growth. The article suggests that the stock may have been over-hyped before. Investors in MediWound have experienced a total loss of 21% in the past year, compared to a market gain of 14%. The article advises considering other factors and warns of investment risks. The article does not mention any specific customers, partners, investors, or acquisition or investment amounts. The date of the event described in the article is not provided.
Customers
growth-positive
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
MediWound Ltd. announces its participation in the upcoming Healthcare Virtual Conference Part II. The CEO will participate in a fireside chat. The company is a global leader in enzymatic therapeutics for tissue repair and is focused on non-surgical solutions that improve patient outcomes and reduce costs. Their first drug, NexoBrid, is FDA-approved for eschar removal in severe burns. They also have a strong R&D pipeline, including EscharEx for debridement of chronic wounds and MW005 for basal cell carcinoma. The Phase III study for EscharEx is expected to start in Q4 2023. The company website is www.mediwound.com.
PartnersExpand
growth-negative
Analyst Forecasts Just Became More Bearish On MediWound Ltd. (NASDAQ:MDWD)
Analysts have revised their revenue forecasts for MediWound, signaling a weaker outlook and a substantial decline in sales. The consensus now predicts revenues of US$18m in 2023, a 31% decline compared to the previous year. The loss per share is expected to narrow by 35%. The analysts downgrade does not appear to have a long-term impact on MediWounds valuation, as the consensus price target remains unchanged. However, the wide range of price targets suggests a diverse view on the companys future. MediWounds revenue decline is expected to be much worse than the industry average, indicating a significant underperformance. This downgrade may lead to increased caution from the market. The article also highlights potential issues with MediWounds business, such as dilution from new stock issuance.
Customers
growth-positive
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
MediWound Ltd. has announced its financial results for Q1 2023, revealing a strong financial position with over $57 million in cash. The company is set to initiate the Phase III study for its flagship product, EscharEx, in Q4 2023, and expects to launch NexoBrid in the US in Q3 2023. MediWound has also received a $7.5 million milestone payment from Vericel and an additional $10 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). The company has strengthened its management team and raised $27.5 million in a registered direct offering of ordinary shares.
InvestmentExpandManagement Changes
growth-negative
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound reported a quarterly loss of $0.44 per share, which is worse than the Zacks Consensus Estimate of a loss of $0.31. This is also a significant increase from the loss of $0.84 per share a year ago. The company, which develops treatments for burns and hard-to-heal wounds, posted revenues of $3.8 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 28.66%. This is a decrease from the year-ago revenues of $4.41 million. MediWound shares have lost about 28% since the beginning of the year.
Investment
growth-positive
MediWound to Report First Quarter 2023 Financial Results
MediWound Ltd. will release its financial results for the first quarter ended March 31, 2023 on May 30, 2023. The companys management will host a conference call and webcast to discuss the financial results, provide corporate updates, and answer questions. MediWound is a global leader in next-generation enzymatic therapeutics for tissue repair, specializing in the development, production, and commercialization of solutions that improve patient experiences and outcomes while reducing costs and unnecessary surgeries. The companys first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns. MediWound also has a strong R&D pipeline, including EscharEx® for debridement of chronic wounds and MW005 for basal cell carcinoma.
Management ChangesExpand
growth-positive
MediWound Announces an Additional $10 Million Award from BARDA
MediWound Ltd. has received an additional $10 million in funding from BARDA to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension. The funding will also enable the replenishment of expired products previously procured for emergency preparedness. The partnership with BARDA has been instrumental in the successful development of NexoBrid, and MediWound is excited to make it available in the U.S. market. The company plans to expand the indication of NexoBrid to include the treatment of pediatric burn victims. The funding will also support the enrollment of additional patients in the ongoing expanded access treatment protocol. MediWound was awarded its first BARDA contract in 2015, and the cumulative funding under both contracts is now valued at up to $216 million.
InvestmentPartners
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
growth-negative
Pinning Down MediWound Ltd.'s (NASDAQ:MDWD) P/S Is Difficult Right Now
The article discusses the high price-to-sales (P/S) ratio of MediWound Ltd. and its impact on the company. The P/S ratio of 4.4x is higher than the industry average, indicating potential overvaluation. The companys revenue growth has been slower than its peers, leading to concerns about the viability of the share price. Despite a 12% growth in revenues last year, the companys overall revenue has shrunk by 17% in the last three years. Analysts predict a weaker revenue result for MediWound compared to the industry average. The article suggests that investors may be setting themselves up for disappointment if the P/S ratio falls to levels more in line with the growth outlook. The article concludes that the high P/S ratio and weak revenue estimate do not justify the current stock prices.
Customers
We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business Growth
growth-negative
MediWound Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
MediWound has reported its full year 2022 results, with a revenue of US$26.5m, up 12% from FY 2021. However, the companys net loss widened by 45% to US$19.6m, and its loss per share further deteriorated from US$3.48 in FY 2021 to US$3.93. Despite revenue exceeding analyst estimates by 23%, earnings per share (EPS) missed analyst estimates by 81%. Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the US.
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
Institutions own 29% of MediWound Ltd. (NASDAQ:MDWD) shares but individual investors control 43% of the company
growth-positive
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
MediWound Ltd., a biopharmaceutical company, has announced the closing of its registered direct offering, raising $27.5 million before deducting placement agent fees and other offering expenses. The company plans to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx, establishing a U.S. commercial presence, supporting business development activities, and for general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
InvestmentExpand
growth-positive
Billionaire Steve Cohen leads $27.5 million investment in MediWound | CTech
MediWound, an Israeli biomed company, has completed a funding round of $27.5 million, with the largest investor being Steve Cohens hedge fund Point72, which invested $15 million. This is believed to be Cohens first investment in Israel. MediWound plans to use the funding to expand its production capacity and develop a medication for healing severe wounds. After the funding round, the company will have approximately $70 million in its coffers. MediWounds annual revenue is approximately $26 million, and the company expects its sales to increase by 65% in 2023. The largest shareholder in MediWound is Clal Biotechnology, which will see its holding drop from 22% to 17% after the new investment.
Investment
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
Buy These 2 Stocks Before They Jump Over 80%, Say Analysts
growth-positive
FDA approves MediWound burns treatment
Yavne-based MediWound has received approval from the US Food and Drug Administration (FDA) for its burn treatment NexoBrid. The product is approved for sale in the US for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns. NexoBrid is already approved in 43 other countries. MediWound will receive a $7.5 million milestone payment from Vericel Corporation triggered by the FDA approval. The US market for NexoBrid as a burn treatment is estimated at $200 million. MediWounds share price closed 4% up on Thursday, and the company has a market cap of $78.5 million. The treatment is based on the pineapple plant and is one of the first botanical drugs to receive FDA approval.
CustomersInvestment
growth-positive
גלובס זירת העסקים של ישראל
Mediwound, an Israeli pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to market its drug, NexoBrid, for the treatment of burns. The drug, which is based on the pineapple plant, is one of the first to receive FDA approval as a botanical drug. The companys shares rose by 4.8% following the announcement, with a valuation of approximately $108 million. Mediwounds marketing partner, Vericel, is expected to begin marketing the product in the coming months.
CustomersPartners
growth-positive
MediWound raises $30m for clinical trial, production expansion
Israeli biopharmaceutical company MediWound Ltd. has raised $30 million through a fundraising round. The funds will be used to finance a Phase III clinical trial and expand the companys production facility. MediWound has developed a preparation for treating burns and is currently undergoing clinical trials for treating wounds. The companys product for treating burns has been sold in the European market for about a decade, generating revenue of $4.7 million in the first quarter. MediWound is also seeking marketing approval in the US, Japan, and India for its burns treatment product. Ofer Gonen, the CEO of Clal Biotechnology, has been appointed as the CEO of MediWound.
InvestmentExpand
growth-positive
MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates
MediWound Ltd., a biopharmaceutical company, has announced its financial results for Q2 2022, with total revenues of $4.7 million, down from $6.1 million in Q2 2021. The company also announced positive results from two Phase 2 clinical studies of its product, EscharEx, for the treatment of venous leg ulcers. Additionally, the FDA has accepted the re-submitted Biologics License Application for NexoBrid, another of the companys products. The company also made several appointments to its board and executive leadership team.
Management ChangesInvestment
growth-positive
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
MediWound Ltd. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for NexoBrid, a product for eschar removal in burn patients. The FDA has set a target date of January 1, 2023, for the review. The BLA re-submission includes manufacturing data, preclinical and clinical studies, and the pivotal U.S. Phase 3 study of NexoBrid. The product is already approved in the European Union and other international markets. Vericel Corporation holds the exclusive license for North American commercial rights to NexoBrid. The development of NexoBrid has been supported by federal funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA).
Customers
growth-positive
MediWound to Host a Key Opinion Leader Investor Day on EscharEx
MediWound Ltd. will host an in-person key opinion leader (KOL) event on EscharEx for analysts and investors. The event will feature presentations by KOLs discussing wound debridement practice, recent clinical study results, and potential market opportunity. The event will also include a company update and future strategic plans. The event will be webcasted for those unable to attend in person. MediWound is a biopharmaceutical company focused on tissue repair and regeneration. EscharEx is a next-generation bioactive topical therapeutic under development for debridement of chronic and hard to heal wounds.
PartnersInvestment
growth-positive
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
MediWound Ltd., a biopharmaceutical company, has announced positive results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers. The study met its primary and key secondary endpoints with statistically significant results. The company anticipates meeting with the U.S. Food and Drug Administration in the second half of 2022 to discuss study results and a potential Phase 3 pivotal plan for EscharEx. The companys CEO, Sharon Malka, expressed excitement about the results and the potential impact of EscharEx on patients lives.
Customers
growth-positive
MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
MediWound has announced that the Biomedical Advanced Research and Development Authority (BARDA) has provided supplemental funding of $9 million to support the NexoBrid BLA resubmission with the FDA and the ongoing expanded access treatment protocol. This funding will enhance U.S. preparedness for burn patients. MediWound has received a total of up to $211 million in funding from BARDA to support the development of NexoBrid and other potential indications. The company plans to submit the BLA in mid-2022.
Investment
growth-positive
MediWound reports positive results in leg ulcer trial
Israeli biotherapeutic solutions for tissue repair developer MediWound Ltd. reported positive results on a Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers. The study demonstrated that patients treated with EscharEx had a statistically significant higher incidence of complete debridement compared to the gel. The study met its primary endpoint with a p-value of 0.004. MediWound sees the potential for EscharEx to become a best-in-class non-surgical debridement option for chronic wounds. Clal Biotechnology Industries, which has a 35% stake in MediWound, expects interest in the company to strengthen after the trial results.
Customers
growth-positive
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
MediWound Ltd., a biopharmaceutical company, announced a positive outcome from an interim sample size re-estimation of its ongoing EscharEx U.S. phase 2 study for the treatment of venous leg ulcers. The Independent Data Monitoring Committee recommended continuing the study without changes to the sample size, indicating no safety concerns and maintaining statistical power. The study aims to assess the safety and efficacy of EscharEx compared to a placebo control and standard-of-care treatments. MediWound remains on track to complete patient enrollment by year-end 2021, with data readout expected in the first half of 2022. EscharEx is a bioactive therapy for debridement of chronic wounds and has shown promising results in previous trials.
Customers
growth-positive
Israel's MediWound says key trial shows pineapple gel effective for kids' burns
MediWound Ltd., a maker of a pineapple-based gel to treat burn victims, announced positive results of a key Phase 3 clinical trial of its treatment on children with severe thermal burns. The study showed a significant reduction in the time to remove dead tissue caused by a burn and a significant reduction in wound area needing surgery. The gel treatment was also found to be safe and well-tolerated. The results of the study bring the company one step closer to making the treatment available for pediatric burn patients. The clinical trial was funded and supported by the Biomedical Advanced Research and Development Authority.
Customers
growth-positive
MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer
MediWound Ltd. has announced the initiation of a new clinical development program to evaluate its drug product candidate MWPC005 in patients with non-melanoma skin cancer. The company has submitted a protocol to the FDA for a phase I/II clinical study of MWPC005 for the treatment of basal cell carcinoma (BCC) and plans to initiate the study in the second quarter of 2021. A phase II investigator-initiated trial of MWPC005 will also be conducted in parallel in Israel. The company expects data from both studies to be generated by the end of 2021. MWPC005 is a topically applied biological drug candidate based on the same active ingredient as the companys NexoBrid and EscharEx products. The drug candidate has shown potential in treating low-risk non-melanoma skin malignancies.
CustomersPartners
growth-positive
MediWound signs UAE burns treatment distribution deal
MediWound Ltd. has signed a distribution agreement with UAE-based Ghassan Aboud Group (GAG) for the distribution of NexoBrid, a treatment for severe burns, in the UAE. The agreement grants GAG exclusive rights to market and distribute NexoBrid in the region. The partnership is a result of the Abraham Accords Peace Agreement between Israel and the UAE. MediWound expects commercialization to begin within a year upon securing regulatory approval.
Partners
growth-positive
MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
MediWound has completed the enrollment stage of its NexoBrid Phase 3 pediatric clinical study and expects top-line results with 12 months follow-up data in the second half of 2021. The study aims to evaluate the efficacy and safety of NexoBrid compared to standard-of-care in pediatric burn patients. The completion of the enrollment stage follows the FDAs agreement to expand the NexoBrid expanded access protocol to include pediatric patients. The inclusion of pediatric patients in the protocol will allow more physicians to gain experience with NexoBrid and expand the national capacity of trained physicians. MediWounds CEO and Vericels President and CEO both expressed their satisfaction with the progress of the study and the potential of NexoBrid to address the challenges in treating severe burns in children.
CustomersPartners
growth-positive
MediWound Studying the Effect of EscharEx on Biofilm Burden
MediWound Ltd. is exploring the pharmacological effect of EscharEx on biofilm burden associated with chronic wounds. Biofilms are aggregates of microorganisms that are resistant to host defenses and antimicrobial agents, and they are associated with delayed wound healing. Enzymatic debridement, specifically using bromelain enzyme, has shown promise in eradicating biofilms. EscharEx, a mixture of proteolytic enzymes enriched in bromelain, has demonstrated effectiveness in debriding chronic hard-to-heal wounds. MediWound plans to conduct pharmacological studies to assess the effect of EscharEx on biofilm burden. The treatment of biofilm in chronic wounds is becoming a primary objective of wound care, and enzymes could become an important treatment for biofilm elimination. The article highlights the potential impact of EscharEx on patients and the healthcare burden caused by non-healing wounds.
Customers
growth-positive
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
MediWound Ltd. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for NexoBrid, a therapy for eschar removal in burn victims. The FDA has set a target date of June 29, 2021, for the review. The acceptance of the BLA is seen as a major milestone for MediWound, bringing the company one step closer to providing NexoBrid as a treatment option in the United States. The BLA submission includes manufacturing data and clinical studies, including the successful Phase 3 study. NexoBrid is currently approved in the European Union and other international markets. Vericel Corporation holds the exclusive license for North American commercial rights to NexoBrid.
Public Trading
growth-positive
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
MediWound Ltd. and its U.S. commercial partner Vericel Corporation announced that the Biomedical Advanced Research and Development Authority (BARDA) has accepted the first shipment of NexoBrid, a product for the potential emergency treatment of severe thermal burns. The initial procurement of NexoBrid by BARDA is valued at $16.5 million, with additional quarterly deliveries planned through the end of 2021. BARDA also holds an option to procure additional quantities of NexoBrid through funding of up to $50 million. The procurement is part of the Project BioShield contract between MediWound and BARDA, signed in September 2015.
PartnersCustomers
growth-positive
MediWound files for FDA approval for burns treatment
MediWound Ltd. has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the approval of NexoBrid for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The companys share price rose 11.24% on Nasdaq following the news. Vericel Corp. holds an exclusive license for North American commercial rights to NexoBrid. Funding and technical support for the development of NexoBrid is being provided by the US Biomedical Advanced Research and Development Authority (BARDA). The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing.
Investment
growth-positive
MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
MediWound Ltd. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for NexoBrid, its innovative therapy for burn and wound management. The BLA submission includes manufacturing data and clinical studies, including the successful Phase 3 study. NexoBrid is already approved in the European Union and other international markets. Vericel Corporation holds the exclusive license for North American commercial rights to NexoBrid. The development of NexoBrid is being funded and supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA). The FDA has a 60-day review period to determine the completeness and acceptability of the BLA. Upon approval, MediWound is eligible to receive a milestone payment from Vericel.
Investment
growth-positive
MediWound to Supply Pineapple-Based Burn Treatment to U.S. Department of Health
MediWound Ltd. has signed a $16.5 million contract with the U.S. Department of Health and Human Services to supply its pineapple-based burn treatment drug, NexoBrid. The company is expected to begin delivering the product in the first quarter of 2020. In May, MediWound entered a licensing agreement with Vericel Corp. for the exclusive distribution of NexoBrid.
Partners
growth-positive
BARDA Initiates the Procurement of NexoBrid for Emergency Response
MediWound Ltd. and its U.S. commercial partner Vericel Corporation announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has begun procuring NexoBrid® for emergency stockpile. The initial BARDA procurement is valued at $16.5 million, with the first delivery of NexoBrid expected by the end of the first quarter of 2020. Additional deliveries will occur over the subsequent five quarters. BARDA also holds an option to procure additional quantities of NexoBrid through funding of up to $50 million.
PartnersCustomers
growth-positive
Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
Vericel Corporation and MediWound Ltd. have announced the initiation of the NexoBrid expanded access treatment protocol (NEXT) to treat burn patients in the U.S. The protocol, which is supported and funded by the Biomedical Advanced Research and Development Authority (BARDA), allows for the continued clinical use of NexoBrid for U.S. patients prior to its approval by the FDA. The companies anticipate filing the Biologics License Application (BLA) in the second quarter of 2020. The protocol will also extend the number of NexoBrid-trained physicians and healthcare providers in the U.S. and generate additional awareness and use at U.S. burn centers prior to the commercialization of NexoBrid.
PartnersExpand
growth-positive
MediWound Launches EscharEx® U.S. Clinical Development Program
MediWound Ltd. has announced its U.S. clinical development plan for EscharEx, a topical biological drug candidate for the debridement of chronic and hard-to-heal wounds. The company plans to initiate a Phase 2 study in the fourth quarter of 2019 to assess the safety, efficacy, and clinical benefit of EscharEx compared to placebo and non-surgical standard of care. The study is designed to treat venous leg ulcer patients and will enroll 174 patients in approximately 25 clinical sites. MediWound believes that the second generation of EscharEx can better address the unmet medical need for non-surgical rapid and effective treatment. The company also announced its collaboration with Vericel to commercialize NexoBrid in the U.S. and its plans to host an Analyst Day to discuss its development status and clinical development program.
InvestmentPartners
growth-positive
MediWound Appoints Mr. Boaz Gur-Lavie as Chief Financial Officer
MediWound Ltd. has appointed Boaz Gur-Lavie as Chief Financial Officer. Gur-Lavie brings extensive experience in M&As, IPOs, capital raises, investor and public relations, financial strategies, and business development. The appointment is expected to contribute to the companys growth as it advances the development of EscharEx® and expands the use of NexoBrid® in international markets.
Management Changes
growth-positive
NexoBrid® Receives Marketing Authorization from Peru's Ministry of Health
MediWound Ltd. has received authorization from the Ministry of Health in Peru to market and distribute NexoBrid, a therapy for severe burns. Avalon Pharmaceutical Peru S.A.C., MediWounds exclusive distribution partner in Peru, plans to launch NexoBrid in the first half of 2020. This regulatory approval aligns with MediWounds global commercial strategy of expanding the use of NexoBrid in international markets. The company aims to obtain additional marketing approvals through collaboration with local partners. MediWound is focused on developing and commercializing innovative therapies for severe burns and hard-to-heal wounds. Avalon Pharmaceutical is a partner in Latin America for MediWound.
Customers
growth-positive
BARDA Upsizes Support for NexoBrid with an Additional $21 Million to Fund Continuous Access Treatment Protocol for Thermal Burn
MediWound Ltd. has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has provided supplemental funding of $21 million to initiate the NexoBrid expanded access treatment protocol. This brings the total non-dilutive funding under the contract with BARDA to up to $196 million. The NexoBrid expanded access treatment protocol will allow for the ongoing use of NexoBrid to treat burn patients in the U.S. The protocol will be initiated in the third quarter of 2019, alongside the preparation of the NexoBrid Biologics License Application (BLA) for submission in the fourth quarter of this year. The funding and support for the development of NexoBrid have been provided by BARDA.
Investment
growth-positive
MediWound teams with Vericel in North American market
Israeli company MediWound has signed an investment and marketing agreement with Vericel for its NexoBrid burn treatment product. Vericel will pay MediWound a $17.5 million advance, plus $132.5 million in milestone payments and royalties. The deal is fairly large considering it only grants Vericel rights in North America for the burns market, estimated at $200 million. MediWound retains rights to other markets, including Europe. MediWound also has a joint development and acquisition agreement with BARDA. The NexoBrid product is already being sold in Europe and is in advanced clinical trials in the US. MediWound is focusing on promoting its product for chronic wounds.
Partners
growth-negative
MediWound Announces Executive Leadership Changes
MediWound Ltd. announced that CEO Gal Cohen will be stepping down after 12 years. Sharon Malka, the companys CFO and COO, will be appointed as the new CEO. The Chairman of the Board, Stephen T. Wills, will serve as Active Chairman. During Cohens tenure, the company developed and gained marketing approvals for NexoBrid, an orphan drug for burn treatment. The company also raised over $250 million in equity offerings, strategic transactions, and government contracts. Malka expressed his honor in taking on the role and leading the team to advance the companys portfolio of unique products. Wills thanked Cohen for his leadership and contributions to the company. The article also mentions the positive top-line results from the companys Phase 3 study and the ongoing strategic process.
Management Changes
growth-positive
MediWound jumps on positive Phase III burns treatment results
MediWound Ltd, a portfolio company of Clal Biotechnology Industries Ltd., reported positive results in its Phase III trial in the US for its product NexoBrid, a gel designed to remove dead tissue from burn areas. The trial was part of the companys track for gaining approval in the US. The opening of the US market is expected to improve MediWounds revenue and persuade medical centers in Europe to adopt the product. Mediwounds share price increased by 15% in Nasdaq trading. The company plans to register the product for marketing in the US by mid-2019.
Customers
growth-positive
MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns
MediWound Ltd. has announced that it has met its primary and all secondary endpoints in its pivotal U.S. Phase 3 clinical study with NexoBrid to treat patients with deep partial thickness (DPT) and full thickness (FT) thermal burns. The study was funded and supported by the Biomedical Advanced Research and Development Authority (BARDA). The company plans to submit the Biological License Application (BLA) in the second half of 2019 based on the available acute primary, secondary, and safety data with the twelve-month safety follow-up data submitted during the BLA review.
Investment
growth-positive
US seeks to adapt Israeli pineapple-based burn gel to treat mustard gas victims
MediWound has received a new contract worth up to $43 million from the US Biomedical Advanced Research and Development Authority (BARDA) to adapt its gel-based product, NexoBrid, for the treatment of mustard gas injuries. The contract provides $12 million in funding for research and development, with options for additional funding of up to $31 million. MediWound has already received $132 million in funding from BARDA for the development of NexoBrid. The contract is seen as an endorsement of MediWounds technology and will support the companys efforts to develop a non-surgical treatment option for sulfur mustard victims. MediWounds products are based on proteolytic enzymes extracted from the pineapple plant.
Investment
growth-positive
MediWound's Pineapple-Based Burn Treatment to Treat Mustard Gas Burns
MediWound Ltd., a Nasdaq-listed biopharmaceutical company, has received FDA approval to expand the use of its flagship burn treatment drug, NexoBrid, for the treatment of Sulfur Mustard injuries. NexoBrid is a pineapple enzyme-based treatment that removes dead tissue from burn wounds. The FDA approval allows MediWound to market the drug for this additional treatment course without the need for additional clinical trials in humans. The approval is seen as a growth-positive development for the company. MediWound has raised a total of $170 million in funding to date, including $100 million in a public offering. The company was founded in 2001 and employs 46 people in Israel and 21 in Europe.
Expand
Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 Million of PolyHeal Shares;MediWound Weighing an Appeal MediWound
growth-positive
MediWound underwriters buy $3.2m in share options
Pharma company MediWound Ltd. has completed a $25.2 million financing round, with the exercise of underwriters greenshoe options. The funds will be used to fund a Phase III trial of its EscharEx product for healing wounds and to continue development for the US market and a pediatric form of the product. MediWound has developed a method of debridement without surgery that is simpler and more accurate. The burns market is estimated at several hundred million dollars, while the wounds treatment market is believed to be over $1 billion.
Investment
growth-positive
MediWound raises $22m in Nasdaq offering
MediWound Ltd. has successfully completed Phase II trials for its wound treatment product. The company has raised $22 million in a financing round on Nasdaq, with Clal Biotechnology Industries Ltd. holding a 43% stake. MediWound is already marketing its burn treatment product in Europe, but revenue from this product is relatively low. In the US, the company has signed an agreement with BARDA, which will invest an additional $22 million in MediWound. The company is also focusing on a product for treatment of chronic wounds, which has passed Phase II trials and is expected to begin Phase III trials next year. MediWound lost $4.5 million in the second quarter and had $21 million in funds at the end of the quarter.
InvestmentExpand
growth-positive
BARDA to invest $22m in Mediwound's burns treatment
The Biomedical Advanced Research and Development Authority (BARDA) has increased its investment in MediWound Ltd. by $22 million for the companys research and development of its NexoBrid product for burns treatment. BARDA previously committed to investing $24 million in development and purchasing the product. MediWounds share price has risen 36% this year, and the companys market cap is now $158 million. The company is also conducting trials for approval of the product in the US and for treatment of children. MediWound lost $4.3 million in the first quarter and is projected to burn up to $17 million in 2017. Clal Biotechnology, which has a 43% stake in MediWound, has a market cap of NIS 562 million. Clal Biotechnology also announced the success of a Phase I clinical trial by Exithera, in which it has a 54% holding.
Investment
growth-negative
MediWound files to raise $125m in secondary offering
MediWound Ltd., a biomedical company, reported its financial results for the fourth quarter of 2015 and the entire year. The company also submitted a shelf prospectus for raising up to $125 million. MediWound has developed the NexoBrid product for removing damaged tissue in patients with burns. The companys revenue increased by 132% in 2015, thanks to higher sales in Europe and Israel. However, MediWound is still recording losses. The company is planning to conduct a Phase III trial for its burns treatment product in the US. MediWounds net losses in the fourth quarter of 2015 were $7.8 million, and $22.1 million for the year. The company had $46 million in cash at the end of 2015.
Investment
MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S. MediWound
http://www.finances.com/company-news/31451-mediwound-initiates-post-marketing-study-with-nexobridr-to-treat-severe-burns-in-pediatric-patients.htm
growth-positive
MediWound wins $112m US burns treatment deal
MediWound Ltd., a wound and burn care solutions unit of Clal Biotechnology Industries Ltd., has been awarded a $112 million contract by the US Biomedical Advanced Research & Development Authority (BARDA) for its product NexoBrid. The contract is for the removal of dead tissue from medium to severe burns and will be used by US authorities in emergency situations. The deal includes a $24 million payment towards FDA approval, $16 million worth of purchases subject to FDA approval, and an option for $22 million in financing for expanded use of NexoBrid. This contract will contribute to the growth of MediWound Ltd. and its parent company Clal Biotechnology Industries Ltd.
Investment
MediWound Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 121 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
MediWound Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 512894940 |
| Crunchbase | mediwound |
| Phone | +972779714100 |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-07-15T00:00:00.000Z |
| Created | 2014-11-04T00:00:00.000Z |
| Status detail | Public on NASDAQ on Mar, 2014; |